PT  - JOURNAL ARTICLE
AU  - Singh, Mandeep
AU  - Louie, Raymond H. Y.
AU  - Samir, Jerome
AU  - Field, Matthew A.
AU  - Milthorpe, Claire
AU  - Aldiriki, Thiruni
AU  - Mackie, Joseph
AU  - Roper, Ellise
AU  - Faulks, Megan
AU  - Jackson, Katherine J. L.
AU  - Calcino, Andrew
AU  - Hardy, Melinda Y.
AU  - Blombery, Piers
AU  - Amos, Timothy G.
AU  - Deveson, Ira W.
AU  - Read, Scott A.
AU  - Shek, Dmitri
AU  - Guerin, Antoine
AU  - Ma, Cindy S
AU  - Tangye, Stuart G.
AU  - Sabatino, Antonio Di
AU  - Lenti, Marco V.
AU  - Pasini, Alessandra
AU  - Ciccocioppo, Rachele
AU  - Ahlenstiel, Golo
AU  - Suan, Dan
AU  - Tye-Din, Jason A.
AU  - Goodnow, Christopher C.
AU  - Luciani, Fabio
TI  - Expanded T cell clones with lymphoma driver somatic mutations in refractory celiac disease
AID  - 10.1101/2024.03.17.24304320
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.03.17.24304320
4099  - http://medrxiv.org/content/early/2024/03/22/2024.03.17.24304320.short
4100  - http://medrxiv.org/content/early/2024/03/22/2024.03.17.24304320.full
AB  - Intestinal inflammation continues in a subset of celiac disease (CD) patients despite a gluten-free diet. Here, by applying multiomic single cell analysis to duodenal biopsies, we find low-grade malignancies with lymphoma driver mutations in refractory CD type 2 (RCD2) patients comprise surface CD3 negative (sCD3-) lymphocytes stalled at an innate lymphoid cell (ILC) - progenitor T cell stage undergoing extensive TCR recombination. In people with refractory CD type 1 (RCD1), who currently lack explanation, we discover sCD3+ T cells with lymphoma driver mutations forming large clones displaying inflammatory and cytotoxic molecular profiles in 6 of 10 individuals, and a single small clone in 1 of 4 active recently diagnosed CD cases. Accumulation of driver-mutated T cells and their sCD3-progenitors may explain chronic, non-responsive autoimmunity.One-Sentence Summary Treatment refractory autoimmunity in celiac disease may be explained by dysregulated T cells and progenitors that have acquired lymphoma-driver mutations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Bill and Patricia Ritchie Foundation, the Bill Ferris Scholarship, National Health and Medical Research Council Australia (NHMRC) grants APP2010084, APP2028765, APP2010134, APP1113904 and APP1176553, SPHERE Triple I and the UNSW Cellular Genomics Futures Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human Research Ethics Committees from Melbourne Health (approval n. 2020.162) and Western Sydney Health District (n. 2021/ETH01429) gave ethical approvals for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors